Prospective, randomized, and active controlled study of the efficacy of alginic acid and antacid in the treatment of patients with endoscopy-negative reflux disease

Table 5 Summary of the change of quality of life

ITT population	Overall (%)	Topaal (%)	Nacid (%)	P-value
Visit 1/baseline
Observed data				0.9298
No symptom	0 (0.0)	0 (0.0)	0 (0.0)
Moderate symptom	4 (3.3)	3 (4.6)	1 (1.8)
Moderate symptom w/o interfering	29 (24.0)	13 (20.0)	16 (28.6)
Moderate symptom with interfering	61 (50.4)	35 (53.9)	26 (46.4)
Symptom as bad/worse	27 (22.3)	14 (21.5)	13 (23.2)
Study end
Observed data				<0.0001
No symptom	24 (19.8)	19 (29.2)	5 (8.9)
Moderate symptom	51 (42.2)	34 (52.3)	17 (30.4)
Moderate symptom w/o interfering	27 (22.3)	8 (12.3)	19 (33.9)
Moderate symptom with interfering	15 (12.4)	3 (4.6)	12 (21.4)
Symptom as bad/worse	4 (3.3)	1 (1.5)	3 (5.4)
Decrease from baseline				<0.0001
–1	1 (0.8)	0 (0.0)	1 (1.8)
0	24 (19.8)	7 (10.8)	17 (30.4)
1	36 (29.8)	16 (24.6)	20 (35.7)
2	36 (29.8)	22 (33.9)	14 (25.0)
3	16 (13.2)	13 (20.0)	3 (5.4)
4	8 (6.6)	7 (10.8)	1 (1.8)

¹Mantel–Henszel χ2 test.